Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway
Abstract Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impac...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-92687-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774990726004736 |
|---|---|
| author | Yongping Wang Tiantian Zhang Hao Song Cheng Yang |
| author_facet | Yongping Wang Tiantian Zhang Hao Song Cheng Yang |
| author_sort | Yongping Wang |
| collection | DOAJ |
| description | Abstract Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impact on skin fibrosis is less understood. This study investigated the role of ErbB1 and ErbB2 in skin fibrosis and the therapeutic potential of lapatinib, a dual ErbB1 and ErbB2 tyrosine kinase inhibitor. Using qPCR, cell culture assays, Western blotting, and in vivo models, we found significant upregulation of ErbB1 and ErbB2 in keloid tissues and fibroblasts. Lapatinib treatment resulted in a dose-dependent decrease in ErbB1 and ErbB2 expression, which suppressed the expression of fibroblast activation markers. Our findings suggest that lapatinib may be a promising therapeutic agent for skin fibrosis by targeting ErbB1/ErbB2 and modulating the TGF-β1/Smad2/3/Erk/Akt signalling pathways. These results warrant further clinical investigation into lapatinib for treating skin fibrosis and related conditions. |
| format | Article |
| id | doaj-art-0f78e9daed674b06a7e27f48fe3e1755 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0f78e9daed674b06a7e27f48fe3e17552025-08-20T03:01:34ZengNature PortfolioScientific Reports2045-23222025-03-0115111710.1038/s41598-025-92687-1Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathwayYongping Wang0Tiantian Zhang1Hao Song2Cheng Yang3Frontier Science Center for Synthetic Biology (Ministry of Education), Key Laboratory of Systems Bioengineering, School of Chemical Engineering and Technology, Tianjin UniversityState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai UniversityFrontier Science Center for Synthetic Biology (Ministry of Education), Key Laboratory of Systems Bioengineering, School of Chemical Engineering and Technology, Tianjin UniversityState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai UniversityAbstract Skin fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) in the dermis, can lead to hypertrophic scars and impaired mobility. The ErbB family of receptor tyrosine kinases, including ErbB1 and ErbB2, plays a crucial role in organ fibrosis, but their specific impact on skin fibrosis is less understood. This study investigated the role of ErbB1 and ErbB2 in skin fibrosis and the therapeutic potential of lapatinib, a dual ErbB1 and ErbB2 tyrosine kinase inhibitor. Using qPCR, cell culture assays, Western blotting, and in vivo models, we found significant upregulation of ErbB1 and ErbB2 in keloid tissues and fibroblasts. Lapatinib treatment resulted in a dose-dependent decrease in ErbB1 and ErbB2 expression, which suppressed the expression of fibroblast activation markers. Our findings suggest that lapatinib may be a promising therapeutic agent for skin fibrosis by targeting ErbB1/ErbB2 and modulating the TGF-β1/Smad2/3/Erk/Akt signalling pathways. These results warrant further clinical investigation into lapatinib for treating skin fibrosis and related conditions.https://doi.org/10.1038/s41598-025-92687-1Skin fibrosisKeloidSystemic sclerosisFibroblastsLapatinibTGF-β1 signaling pathways |
| spellingShingle | Yongping Wang Tiantian Zhang Hao Song Cheng Yang Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway Scientific Reports Skin fibrosis Keloid Systemic sclerosis Fibroblasts Lapatinib TGF-β1 signaling pathways |
| title | Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway |
| title_full | Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway |
| title_fullStr | Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway |
| title_full_unstemmed | Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway |
| title_short | Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway |
| title_sort | lapatinib ameliorates skin fibrosis by inhibiting tgf β1 smad and non smad signaling pathway |
| topic | Skin fibrosis Keloid Systemic sclerosis Fibroblasts Lapatinib TGF-β1 signaling pathways |
| url | https://doi.org/10.1038/s41598-025-92687-1 |
| work_keys_str_mv | AT yongpingwang lapatinibamelioratesskinfibrosisbyinhibitingtgfb1smadandnonsmadsignalingpathway AT tiantianzhang lapatinibamelioratesskinfibrosisbyinhibitingtgfb1smadandnonsmadsignalingpathway AT haosong lapatinibamelioratesskinfibrosisbyinhibitingtgfb1smadandnonsmadsignalingpathway AT chengyang lapatinibamelioratesskinfibrosisbyinhibitingtgfb1smadandnonsmadsignalingpathway |